Dee Chaudhary | Principal Counsultant, Market Access and Pricing
Clarivate Analytics (UK) Limited
Dee Chaudhary is a Principal in Clarivate’s Commercial Strategy Consulting practice, bringing over 20 years of experience across life sciences consulting and the MedTech and biopharmaceutical industries. She specializes in pricing and market access strategy, launch readiness, and market assessments, with deep expertise spanning reimbursement strategy, 340B pricing, product positioning, patient journey design, and hub services. Dee has particular depth in rare disease and orphan drug strategy, where complex access and evidence considerations are critical to commercialization success. Dee has led high-impact engagements across a broad range of therapeutic areas, including oncology, cell and gene therapies, ophthalmology, biosimilars, diabetes, and rare diseases. She brings a global perspective, with experience spanning the U.S., LATAM, APAC, and European markets, and deep knowledge of evolving payer dynamics across these regions. A recognized thought leader in market access, Dee has presented at ISPOR, multiple global pharmaceutical forums, and Asembia—where she has been invited to speak four times. Her perspectives have also been featured in leading publications such as Forbes, U.S. News & World Report, and Pharmaceutical Executive. Prior to joining Clarivate, Dee held senior leadership roles across both emerging and established MedTech and biopharmaceutical companies, as well as consulting organizations. She holds an MBA in Healthcare Administration and a BA in History from Gustavus Adolphus College.
Appearances:
Pre-Conference Day - World Orphan Drug Congress USA 2026 @ 12:00
Workshop: Most Favoured Nation (MFN) and International Reference Pricing (IRP) for Orphan Medicines and the Future of European Access and Launch Strategy
As global pricing pressure intensifies and discussions around Most Favoured Nation (MFN) drug pricing and International Reference Pricing (IRP) continue to evolve, biotech and specialty pharmaceutical companies are reassessing how, where and when they commercialise products in Europe. This interactive executive workshop hosted by Sciensus at the World Orphan Drug Congress USA will bring together industry leaders, market access specialists and commercial strategists to explore the practical implications these developments may have on European launch sequencing, early access strategy, pricing risk and operational infrastructure. Key Discussion Themes:-
- How MFN and IRP could reshape European launch sequencing
- Why Europe may now directly influence US commercial strategy
- The growing role of early access and alternative commercial models
- How operational flexibility is becoming a competitive advantage
- What leadership teams should prioritise over the next 12–24 months
The session is designed as a highly interactive workshop combining expert insight, live audience polling, strategic scenario exercises and moderated discussion. Attendees will have the opportunity to pressure-test current assumptions around European commercialisation and explore how companies are adapting launch and access models in response to an increasingly complex global pricing environment.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events